Verrica Pharmaceuticals Inc.
This is a Phase 2, open-label study (Study VP-CW-304; referred to as COVE-5 \[Cantharidin and Occlusion in Verruca Epithelium 5\]) to evaluate the safety and systemic exposure of YCANTH (VP-102) following a single 24-hour dermal application in subjects with common warts.
Inclusion Criteria: * Male or female patients aged 2 years or older. * Immunocompetent. * Have a minimum of 4 treatable common warts (verruca vulgaris). Warts in the eye area (including eyelids), lips, oral or nasal cavities, inside the ears, soles of the feet, subungual spaces, anogenital area, or within 10 mm of a mucosal surface will not be treated or evaluated. * Have no systemic or dermatologic disorder that, in the opinion of the investigator, could interfere with the study results or increase the risk of adverse events. * Agree to refrain from swimming, bathing, or prolonged immersion…
YCANTH (VP-102) is supplied as a topical solution containing cantharidin 0.7% w/v in a single-use glass ampule applicator. The solution will be applied to the entirety of each common wart selected for treatment, including an approximate 1 to 2 mm margin of surrounding healthy skin. No more than 2 applicators may be used. Occlusive tape will be applied after the solution has dried and will remain in place overnight until removal at approximately 24 hours.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.